-
Mashup Score: 8
Objective To determine the effect of subclinical synovitis on the progression of joint disease in a cohort of patients with systemic lupus erythematosus over a …
Source: journals.sagepub.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 10
Background Remission is a key treatment target in systemic lupus erythematosus (SLE) management. Given the direct correlation between lupus flares and elevated risks of adverse pregnancy outcomes (APOs), securing remission before conception becomes crucial. However, the association between clinical remission with active serology, and the risk of APOs is not thoroughly understood. Additionally, determining the optimal glucocorticoid dosage during pregnancy to mitigate APO risks remains under-researched. This study investigated the risk of APOs in relation to remission/serological activity status in patients in clinical remission/glucocorticoid dosage. Methods Pregnant patients with SLE, who were followed up at two Japanese tertiary referral centers, and had their remission status assessed at conception, were included in this study. We categorized the patients into two groups based on whether they achieved Zen/Doria remission at conception and analyzed the APO ratio. We also examined the
Categories: General Medicine News, General HCPsTweet
-
Mashup Score: 12KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasis - 1 month(s) ago
Objective A recent genome-wide association study linked KLF2 as a novel Asian-specific locus for systemic lupus erythematosus (SLE) susceptibility. However, the underlying causal functional variant(s), cognate target gene(s) and genetic mechanisms associated with SLE risk are unknown. Methods We used bioinformatics to prioritise likely functional variants and validated the best candidate with diverse experimental techniques, including genome editing. Gene expression was compared between healthy controls (HCs) and patients with SLE with or without lupus nephritis (LN+, LN−). Results Through bioinformatics and expression quantitative trait locus analyses, we prioritised rs4808485 in active chromatin, predicted to modulate KLF2 expression. Luciferase reporter assays and chromatin immunoprecipitation-qPCR demonstrated differential allele-specific enhancer activity and binding of active histone marks (H3K27ac, H3K4me3 and H3K4me1), Pol II, CTCF, P300 and the transcription factor PARP1. Chro
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 108Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial - 2 month(s) ago
Mycophenolate mofetil is an immunosuppressant commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is a known teratogen associated with significant toxicities, including an increased risk of infections and malignancies. Mycophenolate mofetil withdrawal is desirable once disease quiescence is reached, but the timing of when to do so and whether it provides a benefit has not been well-studied. We aimed to determine the effects of mycophenolate mofetil withdrawal on the risk of clinically significant disease reactivation in patients with quiescent SLE on long-term mycophenolate mofetil therapy.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 6Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk - 3 month(s) ago
Abstract Objectives. Cardiovascular disease through accelerated atherosclerosis is a leading cause of mortality for patients with systemic lupus erythematosus (
Source: academic.oup.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Belimumab vs. Oral Immunosuppressants: Infection Risk in Patients with Non-Renal SLE - The Rheumatologist - 5 month(s) ago
Materne et al. investigated the comparative risk of infection with belimumab, an injectable immunosuppressant, vs. oral immunosuppressants for the treatment of systemic lupus erythematosus (SLE). The researchers designed and emulated hypothetical target trials to estimate the cumulative incidence and hazard ratios of serious infection and hospitalization using data from TriNetX, a federated electronic health record database. In three parallel arms, they separately compared initiation of belimumab with azathioprine, belimumab with methotrexate, and belimumab with mycophenolate. Belimumab was associated with lower risks of serious infection than oral immunosuppressants.
Source: www.the-rheumatologist.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Good efficacy achieved by telitacicept, corticosteroids, and immunosuppressants in the treatment of SLE combined with MOG-AD - 5 month(s) ago
Mengxue Tian, Lin Tang; Good efficacy achieved by telitacicept, corticosteroids, and immunosuppressants in the treatment of SLE combined with MOG-AD, Rheumatolo
Source: academic.oup.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis | Lupus Science and Medicine Podcast - 5 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article – http://dx.doi.org/10.1136/lupus-2023-000932
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022 - 6 month(s) ago
AbstractObjective. To estimate mortality and survival rates of systemic lupus erythematosus (SLE) in a contemporary, population-based setting and assess potenti
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis | Lupus Science and Medicine Podcast - 6 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article – http://dx.doi.org/10.1136/lupus-2023-000932
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
91 #SLE pts w/ no baseline synovitis, underwent Ultrasound exams. 10 yrs later, 31 had clinical progression of arthritis. Pts w/ progression, 75% had baseline subclinical synovitis on US vs without progression 77% did NOT have an abnormal US at baseline https://t.co/MN9wkNgsQV https://t.co/ozgvjFI531